Aarti Pharmalabs Limited has informed the Exchange about Investor Presentation
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs submitted its investor presentation from the 6th AGM held on September 22, 2025. The company showcased strong FY25 consolidated performance with revenue of ₹2,115 crore (up 14.2% YoY), EBITDA of ₹464 crore (up 20.3%), and PAT of ₹272 crore (up 25.6%); EBITDA margin expanded 112 bps to 21.96% and PAT margin rose 117 bps to 12.88%. Diluted EPS grew 25.5% to ₹30.04, while ROCE improved to 16.2% and ROE to 13.7%. The business mix is shifting toward higher-value CDMO/CMO (43.5% of Q4-FY25 revenue vs 36.1% in FY24). The company highlighted its A+ credit rating, low Net Debt/Equity of 0.19x, and upcoming Phase 1 commissioning at its Atali greenfield site with 450+ kL reactor capacity.
Positive — the filing reaffirms strong FY25 results with sustained margin expansion and a healthy balance sheet, while flagging capacity expansion that could support future growth. No new material announcement beyond the standard AGM disclosure.